We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Controlling Calcium Homeostasis Could Stabilize Alzheimer's Disease

By Biotechdaily staff writers
Posted on 28 Jul 2008
Two new studies have found that controlling intracellular calcium homeostasis appears to play an important role in controlling levels of amyloid ß (Aß) protein, a major component of the senile plaques that characterize Alzheimer's disease (AD).

Researchers at the department of neurobiology and behavior at the University of California Irvine (USA), reported that the sarco ER Ca2+-ATPase (SERCA) system, which pumps excess Ca2+ into the endoplasmic reticulum (ER) or its muscle equivalent, the sarcoplasmic reticulum (SR), has diminished activity in cells lacking presenilin-1 and presenilin-2 (PS1, PS2). More...
The deficiencies are associated at the cellular level with increased production of the proteotoxic peptide Aß1-42, and at the organismal level with increased risk of early-onset AD. Modulation of SERCA activity on its own can affect the rate of Aß synthesis. Taken together, the data argue that PS1 and PS2 regulate intracellular Ca2+, and that calcium in turn influences production of Aß (and thereby the risk and progression of AD).

Another study, by researchers at the Feinstein Institute for Medical Research (Manhasset, NY, USA) identified CALHM1, a calcium pump on the plasma membrane (as opposed to the ER/SR membrane) that is also involved in Aß production. A naturally occurring polymorphism in the CALHM1 gene is strongly associated with AD; the authors propose that the mutation interferes with Ca2+ permeability and that this alters Aß expression via an as-yet-undetermined mechanism.

When combining the two studies, calcium is seen to be moving in opposite directions; SERCA pumps Ca2+ out of the cytosol into the ER/SR, so a deficiency in SERCA would increase cytosolic Ca2+. In contrast, CALHM1 pumps Ca2+ into the cytosol, so that a deficiency in that protein would decrease cytosolic Ca2+. However, deficiencies in either gene promote AD. The studies suggest that the similar effects on Aß levels are mediated by two very different mechanisms.

Amyloid ß is a peptide that is the main constituent of amyloid plaques in the brains of Alzheimer's disease patients. Amyloid ß also forms aggregates coating cerebral blood vessels in cerebral amyloid angiopathy. These plaques are composed of a tangle of regularly ordered fibrillar aggregates called amyloid fibers, a protein fold shared by other peptides such as prions associated with protein misfolding diseases. Research on laboratory rats suggests that the two-molecule, soluble form of the peptide is a causative agent in the development of AD.


Related Links:
University of California Irvine
Feinstein Institute for Medical Research

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.